0000000000400205

AUTHOR

N. Brack

showing 4 related works from this author

Induction Therapy with Idarubicin, Ara-C, and VP-16, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for High-Risk AML

1996

Aggressive chemotherapy followed by administration of G-CSF and maintenance therapy with interleukin-2 was evaluated in 16 patients with advanced myelodxysplastic syndrome, 47 patients with AML evolving from myelodysplastic syndromes, 3 patients with subacute myeloid leukemia and 5 patients with secondary AML. Median age was 59 years (range: 23 to 76 years). All patients achieving a complete remission (CR) after two induction courses went on to receive two consolidation courses, to be followed by randomization to either high-dose or low-dose IL-2 to evaluate the potential of IL-2 to eliminate residual leukemic cells and to prolong the duration of CR. Patients ≤ age 55 with an HLA identical …

Interleukin 2medicine.medical_specialtyAcute leukemiaChemotherapyRandomizationbusiness.industrymedicine.medical_treatmentMyelodysplastic syndromesImmunotherapymedicine.diseaseGastroenterologyMaintenance therapyInternal medicinemedicineIdarubicinbusinessmedicine.drug
researchProduct

Chemotherapy with Idarubicin, Ara-C,VP-16, Amsacrine, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for Patients with High-Risk …

1998

To improve the complete remission (CR) rate and to prolong CR duration in patients with advanced MDS, AML evolving from MDS, and secondary AML, a phase-III trial of aggressive chemotherapy followed by G-CSF was initiated in January 1992. Pts. achieving a CR were randomized to receive either high-dose or low-dose IL-2 to evaluate the potential of this cytokine to eliminate residual leukemic cells and to prolong the CR duration.

Interleukin 2Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentMyeloid leukemiaImmunotherapyCytokinehemic and lymphatic diseasesInternal medicinemedicineIdarubicinbusinessAmsacrineARA-C/VP-16medicine.drug
researchProduct

Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and h…

2000

Intensive chemotherapy followed by treatment with interleukin-2 (IL-2) was evaluated in a prospective, randomized, multicenter trial including 18 patients with refractory anemia with excess of blasts in transformation (RAEB-T), 86 patients with acute myeloid leukemia (AML) evolving from myelodysplastic syndromes, and six patients with secondary AML after previous chemotherapy. Median age was 58 years (range: 18-76 years). Forty-nine patients (45%) achieved a complete remission (CR) after two induction cycles with idarubicin, ara-C, and etoposide, 52% of them aged/=60 years and 35% aged60 years (p=0.06). After two consolidation courses, patients were randomized to four cycles of either high-…

AdultMalemedicine.medical_specialtyAdolescentGastroenterologyInternal medicineMulticenter trialAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineIdarubicinProspective StudiesSurvival rateEtoposideAgedEtoposideDose-Response Relationship Drugbusiness.industryMyelodysplastic syndromesCytarabineHematologyGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival RateLeukemiaLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseCytarabineInterleukin-2FemaleImmunotherapyIdarubicinbusinessRefractory anemia with excess of blastsmedicine.drugAnnals of Hematology
researchProduct

The rapid atmospheric monitoring system of the Pierre Auger Observatory

2012

The Pierre Auger Observatory is a facility built to detect air showers produced by cosmic rays above 1017 eV. During clear nights with a low illuminated moon fraction, the UV fluorescence light produced by air showers is recorded by optical telescopes at the Observatory. To correct the observations for variations in atmospheric conditions, atmospheric monitoring is performed at regular intervals ranging from several minutes (for cloud identification) to several hours (for aerosol conditions) to several days (for vertical profiles of temperature, pressure, and humidity). In 2009, the monitoring program was upgraded to allow for additional targeted measurements of atmospheric conditions shor…

[PHYS.ASTR.HE]Physics [physics]/Astrophysics [astro-ph]/High Energy Astrophysical Phenomena [astro-ph.HE]AstronomyFOS: Physical sciencesCosmic rayReal-time monitoring01 natural sciencesLarge detector systems for particle and astroparticle physics Real-time monitoring Control and monitor systems onlineOptical telescopeObservatory0103 physical sciencesSHOWERSLarge detector systems for particle and astroparticle physics; Real-time monitoring; Control and monitor systems onlineFLUORESCENCE010303 astronomy & astrophysicsInstrumentationInstrumentation and Methods for Astrophysics (astro-ph.IM)DETECTORMathematical PhysicsRemote sensingEvent reconstructionPierre Auger ObservatoryHigh Energy Astrophysical Phenomena (astro-ph.HE)010308 nuclear & particles physicsLarge detector systems for particle and astroparticle physicsControl and monitor systems online[SDU.ASTR.HE]Sciences of the Universe [physics]/Astrophysics [astro-ph]/High Energy Astrophysical Phenomena [astro-ph.HE]FísicaENERGY-SPECTRUMMonitoring programControl and monitor systems online; Large detector systems for particle and astroparticle physics; Real-time monitoringAerosolATMOSFERA (MONITORAMENTO)Air showerExperimental High Energy PhysicsFísica nuclearAstrophysics - Instrumentation and Methods for AstrophysicsAstrophysics - High Energy Astrophysical Phenomena
researchProduct